PRKAR2A Antikörper (Middle Region)
-
- Target Alle PRKAR2A Antikörper anzeigen
- PRKAR2A (Protein Kinase, CAMP-Dependent, Regulatory, Type II, alpha (PRKAR2A))
-
Bindungsspezifität
- Middle Region
- Reaktivität
- Human, Ratte, Maus, Hund, Schwein, Rind (Kuh), Pferd, Meerschweinchen, Kaninchen
-
Wirt
- Kaninchen
-
Klonalität
- Polyklonal
-
Konjugat
- Dieser PRKAR2A Antikörper ist unkonjugiert
-
Applikation
- Western Blotting (WB)
- Sequenz
- DILVTKDNQT RSVGQYDNRG SFGELALMYN TPRAATIVAT SEGSLWGLDR
- Homologie
- Cow: 100%, Dog: 100%, Guinea Pig: 93%, Horse: 100%, Human: 100%, Mouse: 100%, Pig: 100%, Rabbit: 93%, Rat: 100%
- Produktmerkmale
- This is a rabbit polyclonal antibody against PRKAR2A. It was validated on Western Blot.
- Aufreinigung
- Affinity Purified
- Top Product
- Discover our top product PRKAR2A Primärantikörper
-
-
- Applikationshinweise
- Optimal working dilutions should be determined experimentally by the investigator.
- Kommentare
-
Antigen size: 404 AA
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Liquid
- Konzentration
- Lot specific
- Buffer
- Liquid. Purified antibody supplied in 1x PBS buffer with 0.09 % (w/v) sodium azide and 2 % sucrose.
- Konservierungsmittel
- Sodium azide
- Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Handhabung
- Avoid repeated freeze-thaw cycles.
- Lagerung
- -20 °C
- Informationen zur Lagerung
- For short term use, store at 2-8°C up to 1 week. For long term storage, store at -20°C in small aliquots to prevent freeze-thaw cycles.
-
- Target
- PRKAR2A (Protein Kinase, CAMP-Dependent, Regulatory, Type II, alpha (PRKAR2A))
- Andere Bezeichnung
- PRKAR2A (PRKAR2A Produkte)
- Synonyme
- PKR2 antikoerper, PRKAR2 antikoerper, prkar2a antikoerper, zgc:85886 antikoerper, PRKAR2A antikoerper, 1110061A24Rik antikoerper, AI317181 antikoerper, AI836829 antikoerper, RII(alpha) antikoerper, protein kinase cAMP-dependent type II regulatory subunit alpha antikoerper, protein kinase, cAMP-dependent, regulatory, type II, alpha, B antikoerper, protein kinase, cAMP-dependent, regulatory, type II, alpha antikoerper, protein kinase, cAMP dependent regulatory, type II alpha antikoerper, protein kinase cAMP-dependent type 2 regulatory subunit alpha antikoerper, PRKAR2A antikoerper, prkar2ab antikoerper, Prkar2a antikoerper
- Hintergrund
-
CAMP is a signaling molecule important for a variety of cellular functions. cAMP exerts its effects by activating the cAMP-dependent protein kinase, which transduces the signal through phosphorylation of different target proteins. The inactive kinase holoenzyme is a tetramer composed of two regulatory and two catalytic subunits. cAMP causes the dissociation of the inactive holoenzyme into a dimer of regulatory subunits bound to four cAMP and two free monomeric catalytic subunits. Four different regulatory subunits and three catalytic subunits have been identified in humans. The protein encoded by this gene is one of the regulatory subunits. This subunit can be phosphorylated by the activated catalytic subunit. It may interact with various A-kinase anchoring proteins and determine the subcellular localization of cAMP-dependent protein kinase. This subunit has been shown to regulate protein transport from endosomes to the Golgi apparatus and further to the endoplasmic reticulum (ER).
Alias Symbols: MGC3606, PKR2, PRKAR2
Protein Interaction Partner: UBC, SUZ12, IMPDH2, GPS1, CSRP1, KPNA6, PRKACB, PRKACA, GCH1, WASF1, VCP, CIRBP, ELAVL1, PJA2, Dynll1, AKAP7, PPP1CB, MYCBPAP, ARFGEF2, AKAP2, RAB32, NBEA, AKAP12, AKAP11, AKAP10, AKAP8, AKAP6, AKAP3, AKAP5, AKAP13, AKAP9, CBFA2T3, SMAD3, AKAP1, CFTR, SMA
Protein Size: 404 - Molekulargewicht
- 44 kDa
- Gen-ID
- 5576
- NCBI Accession
- NM_004157, NP_004148
- UniProt
- P13861
- Pathways
- Hedgehog Signalweg, EGFR Signaling Pathway, Neurotrophin Signalübertragung, Myometrial Relaxation and Contraction, G-protein mediated Events, Interaction of EGFR with phospholipase C-gamma, SARS-CoV-2 Protein Interaktom, Phosphorylierungen bei SARS-CoV-2 Infektion
-